Clinical Validation of the Intermediate-risk NMIBC Scoring System and Substratification Model Proposed by the IBCG (International Bladder Cancer Group): A Multicenter YAU Urothelial Working Group Collaboration European Urology Oncology Paolo Gontero francesco soria authors.elsevier.com/c/1jIAG9Cfv--d… a🧵

JUST IN: Durvalumab extends EFS and OS In muscle-invasive bladder cancer —major news with IO moving earlier stages in balder cancer ! OncoAlert Oncology Times Oncology Brothers Tom Powles Targeted Oncology OncLive.com astrazeneca.com/media-centre/p…

Last day at BUMC and Texas Oncology. Bittersweet. 21 years, so much has been accomplished yet seems like yesterday. Off to Texas Tech University Health Sciences Center

Please consider enrolling at your institution. Matt Galsky and I discuss the importance of the @AllianceNCTN A032103 MODERN study, a ctDNA 🧬 informed approach to adjuvant bladder cancer therapy. MRD+ patients get PD1 or PD1/LAG3 Bladder Cancer Advocacy Network Jonathan Rosenberg MD Andrea Apolo, M.D.

Bladder surgery sparing approaches will superceed cystectomy according to Andrea Necchi . #GUARDSymposium2024

It's with great pleasure that I share with you our paper evaluating #cabozantinib with #nivolumab +/- #CBM588 in pts with advanced #kidneycancer, published today in Nature Medicine! 🙏Huge thanks 1st/foremost to patients & their families. Had tons of support from the amazing

Looking forward to the IU ASCO Review on Saturday July 13th to recap data from ASCO2024. Terrific lineup of speakers including Keynote by Matt Galsky discussing the value of circulating tumor DNA in Oncology. iu.cloud-cme.com/course/courseo… IU Simon Comprehensive Cancer Center IU School of Medicine IU School of Medicine Department of Medicine

Please join BCAN in offering congratulations to Jonathan Anker, Ph.D. (Jon Anker, MD, PhD) of Icahn School of Medicine at Mount Sinai on his 2024 BCAN Young Investigator Award. You can learn more about the award and Dr. Anker's proposal here: bcan.org/bcan-announces…

Thank you for the award Bladder Cancer Advocacy Network! Honored to be selected Matt Galsky Bhardwaj Lab The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai

Keynote speaker Dr. Mat Galsky Matt Galsky discussing the value of circulating tumor DNA in Oncology - IU ASCO REVIEW 2024 IU Simon Comprehensive Cancer Center IU School of Medicine Department of Medicine IU School of Medicine

We are proud to share that The Mount Sinai Hospital's cancer service is ranked No. 8 in the nation by U.S. News & World Report® for 2024-25. Mount Sinai Health System

Grateful for the 2024 Bladder Cancer Advocacy Network Innovation Award! This exciting collaboration between my lab Weill Cornell Medicine & Jaehee Kim Cornell University will develop Bio-Digital Avatars to personalize treatments by integrating organoids, ctDNA, math models & deep RL bcan.org/2024-bladder-c…

Could not be prouder of this dear friend & colleague who is making tidal waves of change in #bladdercancer & more. A well deserved promotion, no doubt!

MODERN (A032103) is open and enrolling! Available through the CTSU. Bladder Cancer Advocacy Network World Bladder Cancer Patient Coalition Alliance for Clinical Trials in Oncology ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network CCTG National Cancer Institute UroToday.com Natera Alan Tan Stephanie Berg Society for Immunotherapy of Cancer International Society of Liquid Biopsy

Second Stone Roses tweet I have seen today…? Tom Powles

Results of chemo+IO have produced inconsistent results in urothelial cancer. Opposing effects of pro- and anti-inflammatory changes may explain some of this. Uromigos Laura S. Mertens MarleenKokLab Myriam Chalabi Petros Grivas Matt Galsky The Netherlands Cancer Institute Tom Powles aacrjournals.org/clincancerres/…

Happy to provide the first announcement of a global consensus meeting that will be held in person and virtually on Saturday December 14 2024 at Ospedale San Raffaele the day after our #GURetreat24 | the topic will be the definition of clinical CR after neoadjuvant therapies for #MIBC

Fiery discussion on minimal residual disease for #bladdercancer — ctDNA to replace radiology for disease recurrence? Tom Powles says emphatically yes. Brian Rini, MD says maybe complement radiology. We need to await Alliance for Clinical Trials in Oncology #MODERN trial from Matt Galsky Stephanie Berg !

Tian Zhang, MD, MHS Tom Powles Brian Rini, MD Alliance for Clinical Trials in Oncology Matt Galsky Dana Rathkopf Dan George Shilpa Gupta Andrea Apolo, M.D. Neeraj Agarwal, MD, FASCO Tanya Dorff Matt Milowsky Alicia Morgans, MD, MPH Michael Harrison World GU Conference 💯💯👏🏼👏🏼 using MRD right now as a compliment will help us inform so many future decisions. We’re taking this from our Heme colleagues ! A032103/MODERN will be practice changing! 🥰

#BCANTT24 Shilpa Gupta Petros Grivas great talk on implementation science how to take science to practice